1 month NVO’s Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or BZacks
The CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk’s Alhemo for haemophilia A or B with inhibitors.
XThe CHMP of the regulatory body in the EU adopts a positive opinion recommending the approval of Novo Nordisk’s Alhemo for haemophilia A or B with inhibitors.
X